In the Phase 2 obesity trial, gastrointestinal disorders were the most frequent adverse events, reported by roughly 41%-63% of cagrilintide recipients versus about 32% on placebo, with nausea in 20%-47% versus 18% on placebo. Injection-site reactions were also noted. Most effects were mild to moderate.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026The CagriSema combination trials showed a similar pattern, with gastrointestinal events the main safety concern and most described as transient and mild to moderate. Because cagrilintide is investigational, its longer-term safety profile as a monotherapy is not yet well characterized, and there is no approved label documenting rarer risks.
Many people find gastrointestinal effects ease as the body adjusts to a dose. Holding a dose steady before the next step-up and injecting after a lighter meal are commonly discussed ways to limit nausea.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.